Internal Medicine, Infectious Disease · Houston, TX
NPI
1366436263
Since 2005
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
4900 Fannin St
Houston, TX, 77004
Phone (713) 526-9821
Groups this clinician bills Medicare through
Medicare paid, 2024
$282K
3,410 services
Medicare patients, 2024
359
Average age 69
Drug cost, 2024
$16.8M
11,690 prescriptions
Company payments, 2025
$146K
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Joseph C Gathe Jr. was code 99232 (hospital e&m - subsequent), 1,345 times for 136 patients. In total Joseph C Gathe Jr. billed 3,410 services in 17 codes, and Medicare paid $282K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-12-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 1,345 | 136 | $62.57 | $84K |
| 99233 Hospital E&M - Subsequent | Facility | 930 | 154 | $94.14 | $88K |
| 99214 Office E&M - Established | Office | 488 | 188 | $90.59 | $44K |
| 99223 Hospital E&M - Initial | Facility | 179 | 139 | $135.70 | $24K |
| 99215 Office E&M - Established | Office | 161 | 91 | $134.36 | $22K |
| 99231 Hospital E&M - Subsequent | Facility | 109 | 45 | $39.68 | $4,326 |
| 99213 Office E&M - Established | Office | 105 | 61 | $68.60 | $7,203 |
| 99222 Hospital E&M - Initial | Facility | 31 | 29 | $104.63 | $3,244 |
| 99212 Office E&M - Established | Office | 23 | 20 | $40.87 | $940 |
| 99205 Office E&M - New | Office | 17 | 17 | $166.99 | $2,839 |
By year: 2022 $263K for 3,605 services; 2023 $250K for 3,012 services; 2024 $282K for 3,410 services.
Medicare prescription drug claims, 2024
In 2024, the drug Joseph C Gathe Jr. prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 1,062 prescriptions and refills. In total Joseph C Gathe Jr. wrote 11,690 Medicare prescriptions that cost $16.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 1,062 | 1,080 | 125 | $4.4M |
| Prezcobix Darunavir/Cobicistat | 601 | 651 | 76 | $1.6M |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | 411 | 415 | 50 | $2.0M |
| Amlodipine Besylate Generic | 257 | 453 | 55 | $952 |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 255 | 279 | 28 | $1.1M |
| Tivicay Dolutegravir Sodium | 253 | 267 | 28 | $722K |
| Descovy Emtricitabine/Tenofov Alafenam | 251 | 251 | 27 | $563K |
| Ritonavir Generic | 230 | 290 | 32 | $39K |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 205 | 205 | 26 | $761K |
| Dovato Dolutegravir Sodium/Lamivudine | 186 | 196 | 29 | $568K |
| Losartan-Hydrochlorothiazide Losartan/Hydrochlorothiazide | 182 | 414 | 45 | $1,892 |
| Atorvastatin Calcium Generic | 181 | 403 | 49 | $1,509 |
| Valacyclovir Valacyclovir Hcl | 157 | 261 | 48 | $7,560 |
| Methylprednisolone Generic | 149 | 149 | 104 | $1,015 |
| Darunavir Generic | 148 | 152 | 19 | $131K |
Brand drugs: 4,764 claims; generic drugs: 6,903 claims; opioid claims: 89.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Joseph C Gathe Jr. $146K ($146K in general payments such as food, travel and fees) from 20 companies. The largest payer was Gilead Sciences, Inc. with $104K.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 128 | $104K |
| EMD Serono, Inc. MRK.DE | 37 | $40K |
| Abbvie Inc. ABBV | 10 | $920 |
| ViiV Healthcare Company GSK | 23 | $555 |
| Paratek Pharmaceuticals, Inc. | 9 | $218 |
| Theratechnologies Inc. THTX | 5 | $154 |
| Napo Pharmaceuticals Inc | 6 | $151 |
| Merck Sharp & Dohme LLC MRK | 4 | $113 |
| Lilly USA, LLC LLY | 3 | $74.99 |
| La Jolla Pharmaceutical Company | 2 | $45.03 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.